RXRX AI stock prediction, Monte Carlo, and QML research
Recursion Pharmaceuticals is often grouped with AI-enabled biotech and computational biology themes. The stock can respond to both biotech catalysts and AI infrastructure sentiment.
Ticker
RXRX
Exchange / Market
NASDAQ
Sector
AI biotech
Theme
AI-driven drug discovery and computational biology
Today's Public Snapshot
RXRX AI signal and IV regime
Latest backend snapshot: 2026-08-03. Data is rendered only when a public backend snapshot exists.
AI signal
Pending
Next-session model label
Up probability
-
55%+ Bullish, 45% or lower Bearish
IV regime
SQUEEZE_PHASE
Options volatility context
IV view
Squeeze phase
Opportunity score 119.0
How to read the RXRX AI percentage
The percentage is the estimated probability that RXRX closes higher in the next trading session. It is not a long-term price target and it is not a recommendation to buy or sell.
Why IV regime appears before prediction
Options volatility helps separate directional momentum from market-implied risk. Reading IV first makes the AI signal easier to interpret in context.
Historical Accuracy
RXRX historical prediction win rate
Win rate is calculated only from records where the next trading-day close has been verified.
Win rate
60.7%
active
Monthly
60.7%
2026-07 17/28
Verified
28
Minimum 10
Correct
17
Next-session direction
High conf.
53.8%
13 verified records
Updated
2026-08-03
candidate model
RXRX historical prediction records
| Date | Signal | Probability | Bucket | Last close | Actual next close | Change | Result |
|---|---|---|---|---|---|---|---|
| 2026-08-03 | Bullish | 53% | no edge | $3.19 | - | - | Pending |
| 2026-08-03 | Bullish | 53% | no edge | $3.19 | - | - | Pending |
| 2026-07-31 | Bearish | 47% | no edge | $3.00 | $3.18 | 6.18% | Miss |
| 2026-07-31 | Bearish | 47% | no edge | $3.00 | $3.18 | 6.18% | Miss |
| 2026-07-30 | Bullish | 52% | no edge | $2.99 | $3.00 | 0.33% | Correct |
| 2026-07-30 | Bullish | 52% | no edge | $2.99 | $3.00 | 0.33% | Correct |
| 2026-07-29 | Bullish | 54% | no edge | $3.02 | $3.04 | 0.75% | Correct |
| 2026-07-28 | Bullish | 54% | no edge | $2.92 | $2.97 | 1.81% | Correct |
| 2026-07-28 | Bullish | 54% | no edge | $2.92 | $2.97 | 1.81% | Correct |
| 2026-07-27 | Bullish | 54% | no edge | $3.10 | $3.05 | -1.45% | Miss |
| 2026-07-24 | Bullish | 53% | no edge | $2.96 | $3.01 | 1.86% | Correct |
| 2026-07-24 | Bullish | 53% | no edge | $2.96 | $3.01 | 1.86% | Correct |
| 2026-07-23 | Bearish | 47% | no edge | $2.95 | $2.96 | 0.34% | Miss |
| 2026-07-22 | Bearish | 42% | high confidence | $2.99 | $2.99 | 0.00% | Miss |
| 2026-07-21 | Bearish | 47% | no edge | $3.04 | $2.98 | -1.97% | Correct |
| 2026-07-20 | Bearish | 41% | high confidence | $2.90 | $3.08 | 6.02% | Miss |
| 2026-07-17 | Bearish | 43% | medium confidence | $2.96 | $2.89 | -2.36% | Correct |
| 2026-07-16 | Bullish | 51% | no edge | $3.19 | $2.94 | -7.54% | Miss |
| 2026-07-15 | Bullish | 59% | high confidence | $3.42 | $3.02 | -11.82% | Miss |
| 2026-07-15 | Bullish | 59% | high confidence | $3.42 | $3.02 | -11.82% | Miss |
| 2026-07-14 | Bullish | 58% | high confidence | $3.31 | $3.31 | 0.00% | Miss |
| 2026-07-13 | Bearish | 32% | high confidence | $3.50 | $3.34 | -4.61% | Correct |
| 2026-07-10 | Bearish | 31% | high confidence | $3.58 | $3.30 | -7.69% | Correct |
| 2026-07-09 | Bearish | 30% | high confidence | $3.88 | $3.56 | -8.13% | Correct |
| 2026-07-08 | Bearish | 41% | high confidence | $3.71 | $3.76 | 1.48% | Miss |
| 2026-07-07 | Bearish | 28% | high confidence | $3.88 | $3.72 | -4.25% | Correct |
| 2026-07-07 | Bearish | 28% | high confidence | $3.88 | $3.72 | -4.25% | Correct |
| 2026-07-06 | Bullish | 56% | medium confidence | $3.79 | $3.84 | 1.32% | Correct |
| 2026-07-02 | Bullish | 58% | high confidence | $3.75 | $3.96 | 5.46% | Correct |
| 2026-07-02 | Bullish | 58% | high confidence | $3.75 | $3.96 | 5.46% | Correct |
Why Track It
Recursion Pharmaceuticals research context
Track RXRX when you want a biotech-style risk profile with an AI narrative overlay.
Research Angles
- Biotech news can create discontinuous price moves that require scenario analysis.
- Monte Carlo ranges help translate volatility into practical risk bands.
- Batch Prediction is useful for comparing RXRX with other AI and innovation names.
Workflow
How to research RXRX
Start with the module that matches the question, then compare the signal against risk and benchmark context.
Step 1
Run AI Prediction for short-term directional probability.
Step 2
Use Monte Carlo to inspect downside and upside distribution.
Step 3
Compare against SOUN, NVDA, and QQQ for AI-theme confirmation.
FAQ
RXRX stock prediction FAQ
What is this RXRX research page for?
This page organizes Recursion Pharmaceuticals research around AI Prediction, options IV regime context, QML equity-curve diagnostics, historical prediction records, and Monte Carlo risk workflows.
What does the RXRX AI prediction percentage mean?
The percentage is the model's estimated next-session up probability for RXRX. Readings at 55% or higher are labeled Bullish, 45% or lower are labeled Bearish, and the middle range is Neutral.
How is RXRX historical prediction win rate calculated?
Historical win rate only counts verified records where the next trading-day close is available. Pending predictions are not counted as wins or misses.
Why does this page show an IV regime for RXRX?
The IV regime summarizes options-implied volatility context, including skew and demand, so the AI signal can be read beside market-implied risk.
Is this RXRX page investment advice?
No. The page is for research and education only. It does not provide investment advice or a recommendation to buy or sell securities.
Related Research
Compare RXRX with nearby tickers
SOUN
SoundHound AI
Track SOUN when you want to monitor speculative AI application exposure beyond the mega-cap semiconductor trade.
NVDA
NVIDIA
Track NVDA when you need a market-leading AI infrastructure signal and a reference point for semiconductor momentum.
QSI
Quantum-Si
Track QSI when you want a smaller-cap innovation signal that is less directly tied to mega-cap technology beta.